{"doi":"10.1002/acr.25670","title":"Financial Distress and Its Determinants in Rheumatoid Arthritis","abstract":"OBJECTIVE: To quantify the degree of financial distress and identify its determinants in adults with rheumatoid arthritis (RA) given the frequent prolonged use of expensive disease-modifying therapies. METHODS: We identified adults enrolled in the FORWARD databank with either RA or noninflammatory musculoskeletal disease (NIMSKD) completing the Functional Assessment of Chronic Illness Therapy-Comprehensive Score for Financial Toxicity (FACIT-COST) questionnaire. In this cross-sectional study, FACIT-COST was analyzed as a continuous (higher score indicates less financial distress) and binary variable (presence of financial distress with threshold <26). Least Absolute Shrinkage and Selection Operator (LASSO) was applied to linear and logistic regression to select covariates for inclusion in multivariable models. RESULTS: Participants with RA (n = 2,277) had lower FACIT-COST scores, indicating greater financial distress, than those with NIMSKD (n = 1,340) (mean of 30.2 ± SD 9.4 vs mean of 34.0 ± SD 8.4; unadjusted P < 0.001). Assessed as a binary outcome, financial distress was more frequent in participants with RA than participants with NIMSKD (29% vs 15%; unadjusted P < 0.001). Differences in financial distress by diagnosis persisted following multivariable adjustment. Among those with RA, determinants identified in multivariable models included depression (adjusted odds ratio 1.12; 95% confidence interval 1.09-1.16) and disease severity. CONCLUSION: Financial distress is prevalent in adults with RA and appears to be greatest in those with comorbidities, specifically depression, identifying a potential area for intervention. Notably, expensive biologic or targeted synthetic disease-modifying antirheumatic drugs were not associated with FACIT-COST scores.","journal":"Arthritis Care & Research","year":2025,"id":578152,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7306,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":778568,"name":"Yunju Im","orcid":"0000-0001-7596-3803","position":1,"is_corresponding":false},{"id":765130,"name":"Sofia Pedro","orcid":null,"position":2,"is_corresponding":false},{"id":314417,"name":"Ted R. Mikuls","orcid":"0000-0002-0897-2272","position":3,"is_corresponding":false},{"id":71800,"name":"Edward Peters","orcid":"0000-0003-4928-6532","position":4,"is_corresponding":false},{"id":27525,"name":"Kaleb Michaud","orcid":"0000-0002-5350-3934","position":5,"is_corresponding":false},{"id":1375801,"name":"Amber Brown Keebler","orcid":"0000-0002-7246-2859","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-19T02:58:20.638044Z","pmid":"41098026","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}